one weekly semaglutide and Ozempic-like drugs may improve kidney disease outcomes Semaglutide & Tirzepatide Weekly Dose

Clinical evidence specifically examining GLP-1 receptor agonists in UC populations remains limited

These medications suppress appetite, slow digestion, and regulate blood sugar producing average weight loss of 1522.5% of body weight in clinical trials when combined with lifestyle changes

There is huge public concern about this. Unregulated pharmacies including rogue beauty salons can sell the jabs without accessing a patients medical history with the risk that the drugs react with existing conditions, leading to dangerous side effects

It may lead patients to skip meals, lose muscle mass, or develop unsustainable eating patterns which puts the body into panic mode once normal eating resumes